ArticleProstate cancer and prostatic diseases2017
Contemporary management of men with high-risk localized prostate cancer in the United States.
Article in Prostate cancer and prostatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Article
- Prognostic value of pathological sensitivity for high-risk, localized prostate cancer receiving neoadjuvant hormonal therapy combined with radical prostatectomy.Annals of medicine · 2025Article
- Age-specific racial disparities in the incidence of fatal prostate cancer: an analytic deconstruction.JNCI cancer spectrum · 2025Article
- Understanding the hospital safety net Hospital resource limitations impact prostate cancer treatment beyond socioeconomic disparities.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- The association of where patients with prostate cancer live and receive care on racial treatment inequities.Journal of the National Cancer Institute · 2025Article
- Isolating the Drivers of Racial Inequities in Prostate Cancer Treatment.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Surgical Management and Considerations for Patients with Localized High-Risk Prostate Cancer.Current treatment options in oncology · 2024Review
- Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study.Prostate cancer and prostatic diseases · 2023Article
- Racial inequities in the quality of surgical care among Medicare beneficiaries with localized prostate cancer.Cancer · 2023Article
- Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients.Prostate cancer and prostatic diseases · 2021Article
- High-Risk Prostate Cancer: A Very Challenging Disease in the Field of Uro-Oncology.Diagnostics (Basel, Switzerland) · 2021Article
- Surgical management of high-risk, localized prostate cancer.Nature reviews. Urology · 2020Review
- Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score.Metabolomics : Official journal of the Metabolomic Society · 2020Article
- Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England.International journal of cancer · 2019Article
- Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.World journal of urology · 2019Article
- Article
- Management of prostate cancer: NYU Case of the Month, July 2017.Reviews in urology · 2017Article
- Biological roles of filamin a in prostate cancer cells.International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSurgery and radiation-based therapies are standard management options for men with clinically localized high-risk prostate cancer (PCa). Contemporary patterns of care are unknown. We hypothesize the use of surgery has steadily increased in more recent years.
methodsUsing the National Cancer Data Base for 2004-2013, all men diagnosed with high-risk localized PCa were identified using National Comprehensive Cancer Network criteria. Temporal trends in initial management were assessed. Multivariable logistic regression was used to evaluate demographic and clinical factors associated with undergoing radical prostatectomy (RP).
resultsIn total, 127 391 men were identified. Use of RP increased from 26% in 2004 to 42% in 2013 (adjusted risk ratio (RR) 1.51, 95% CI 1.42-1.60, P<0.001), while external beam radiation therapy (EBRT) decreased from 49% to 42% (P<0.001). African American men had lower odds of undergoing RP (unadjusted rate of 28%, adjusted RR 0.69, 95% CI 0.66-0.72, <0.001) compared to White men (37%). Age was inversely associated with likelihood of receiving RP. Having private insurance was significantly associated with the increased use of RP (vs Medicare, adjusted odds ratio 1.04, 95% CI 1.01-1.08, P=0.015). Biopsy Gleason scores 8-10 with and without any primary Gleason 5 pattern were associated with decreased odds of RP (vs Gleason score ⩽6, both P<0.001). Academic and comprehensive cancer centers were more likely to perform RP compared to community hospitals (both P<0.001).
conclusionThe likelihood of receiving RP for high-risk PCa dramatically increased from 2004 to 2013. By 2013, the use of RP and EBRT were similar. African American men, elderly men and those without private insurance were less likely to receive RP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.